Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection-Reference-Cited by-同舟云学术

Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection

Published:2011-09-24 Issue:15 Volume:25 Page:1881-1886
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Elion Richard,Cohen Calvin,Gathe Joseph,Shalit Peter,Hawkins Trevor,Liu Hui C.,Mathias Anita A.,Chuck Steven L.,Kearney Brian P.,Warren David R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference10 articles.

1. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.;Kempf;Antimicrob Agents Chemother,1997

2. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.;Merry;AIDS,1997

3. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.;van Heeswijk;AIDS,1999

4. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents.;Hsu;Clin Pharmacokinet,1998

5. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer.;Xu;ACS Med Chem Lett,2010

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Viral proteases as therapeutic targets;Molecular Aspects of Medicine;2022-12

2. A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection;Retrovirology;2022-10-22

3. Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat;Biomedicines;2021-03-18

4. Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1;HIV Research & Clinical Practice;2020-11-01

5. Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients;AIDS;2020-04-01